Mizuho Securities Reiterates Outperform Following Endo Int'l (ENDP) Sell-Side Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Endo Int'l (ENDP) Announces Statistically Significant Data from Xiaflex Phase 2 in Dupuytren's Disease Nodules
September 30, 2016 7:31 AM EDTEndo Pharmaceuticals Inc., a subsidiary of Endo International plc (Nasdaq: ENDP), announced new data to be presented evaluating the safety and efficacy of XIAFLEX(collagenase clostridium histolyticum) (or CCH) injection under investigation for the treatment of palmar Dupuytren's disease nodules. The findings will be... More
